Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy
Authors' conclusion
Our study highlights the potential utility of alternative dosing regimens of incretin mimetics. Compared with standard once-weekly dosing, costs can be halved and weight loss maintained. These cost-saving results have implications for patients, physicians, insurers, and governments.
Study context
- Population
- Simulated semaglutide and tirzepatide dosing; national-scale scenario in obese US adults
- Comparison
- Alternative dosing regimens (e.g. q2wk) vs standard once-weekly (q1wk) dosing of semaglutide and tirzepatide
- Outcome
- Weight loss efficacy of alternative dosing regimens
Methodological detailsPharmacokinetic (PK)/pharmacodynamic (PD) modelling, Semaglutide: recent PK and PD model; tirzepatide: recent PK model, PD by reparameterizing the semaglutide PD model to tirzepatide clinical data
- PK/PD modelling
- Semaglutide: recent PK and PD model; tirzepatide: recent PK model, PD by reparameterizing the semaglutide PD model to tirzepatide clinical data
Main finding
As reported in the abstract
Weight loss maintained with reduced dose frequency
- Switching from q1wk to q2wk maintains roughly 75% of the weight loss
- With an appropriate increase in dose size, ≈100% of the weight loss is maintained
Secondary outcomes
National-scale budget allocation: q1wk for a fraction of obese US adults vs q2wk for twice as many
- Same budget; q2wk to twice as many adults reduces national obesity and mortality to a much greater degree
Original publication
Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes Obes Metab. Published 14 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →